Arkadiy Stolyar, MD
Psychiatry · Belmont, MANPI 1780651174
Payments from drug & device makers
Across 224 payments — averaging $14,665 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1.9M
- Eli Lilly$724K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$255K
- Biogen$186K
- Janssen Research & Development, LLC$155K
- Merck$55K
- plus $37K from 7 others
Across 9 payments — averaging $2954.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$27K
What the payments were for
- Food & beverage$12100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 150 | $1,873,162 |
| Eli Lilly | 42 | $723,678 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $254,594 |
| Biogen | 6 | $186,293 |
| Janssen Research & Development, LLC | 9 | $155,252 |
| Merck | 3 | $55,216 |
| E.r. Squibb & Sons, L.L.C. | 3 | $16,450 |
| Supernus Pharmaceuticals, Inc. | 1 | $12,170 |
| Teva Pharmaceuticals USA, Inc. | 2 | $4,215 |
| Amgen | 1 | $2,302 |
| Eli Lilly Export S.A. Puerto Rico Branch | 1 | $828 |
| Jazz Pharmaceuticals Inc. | 1 | $825 |
| Corium, LLC | 1 | $12 |
How this compares
$3,284,997 in reported general payments places this provider in the 95th percentile of 1,431 psychiatry providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Duloxetine Hcl | 16 | $285 |
| Mirtazapine | 16 | $136 |
| Olanzapine | 18 | $120 |
| Gabapentin | 15 | $110 |
| Quetiapine Fumarate | 14 | $99 |
| Escitalopram Oxalate | 14 | $77 |
| Trazodone Hcl | 17 | $65 |
| Lorazepam | 13 | $54 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Belmont
- J BodkinBelmont$465K
- Robert AlexanderBelmont$415K
- Miles CunninghamBelmont$258K
- James HudsonBelmont$52K
- Srinivasan PillayBelmont$51K
- Lee CohenBoston$7M
- Dyanna DomiliciBoston$5.8M
- Maurizio FavaBoston$2.8M
- Marc ShayAmesbury$1.7M
- Martha StarkNewton$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.